A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system

Alexandros Marios Sofias; Francis Combes; Steffen Koschmieder; Gert Storm; Twan Lammers

doi:10.1016/j.drudis.2021.02.017

A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system

Alexandros Marios Sofias, Francis Combes, Steffen Koschmieder, Gert Storm, Twan Lammers

Research output: Contribution to journal › Review article › peer-review

Abstract

Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.

Original language	English
Pages (from-to)	1482-1489
Number of pages	8
Journal	Drug Discovery Today
Volume	26
Issue number	6
DOIs	https://doi.org/10.1016/j.drudis.2021.02.017
Publication status	Published - Jun 2021

Bibliographical note

Keywords

Animals
Antineoplastic Agents/administration & dosage
Drug Delivery Systems
Drug Design
Humans
Immunotherapy/methods
Nanomedicine
Nanoparticles
Neoplasms/drug therapy
Tumor Microenvironment/immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2021.02.017

1-s2.0-S1359644621001008-mainFinal published version, 1.01 MBLicence: Taverne

Cite this

@article{646044d5b8b24a29a9c5626ba05ae4cd,

title = "A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system",

abstract = "Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.",

keywords = "Animals, Antineoplastic Agents/administration & dosage, Drug Delivery Systems, Drug Design, Humans, Immunotherapy/methods, Nanomedicine, Nanoparticles, Neoplasms/drug therapy, Tumor Microenvironment/immunology",

author = "Sofias, {Alexandros Marios} and Francis Combes and Steffen Koschmieder and Gert Storm and Twan Lammers",

year = "2021",

month = jun,

doi = "10.1016/j.drudis.2021.02.017",

language = "English",

volume = "26",

pages = "1482--1489",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - A paradigm shift in cancer nanomedicine

T2 - from traditional tumor targeting to leveraging the immune system

AU - Sofias, Alexandros Marios

AU - Combes, Francis

AU - Koschmieder, Steffen

AU - Storm, Gert

AU - Lammers, Twan

PY - 2021/6

Y1 - 2021/6

N2 - Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.

AB - Twenty-five years after the approval of the first anticancer nanodrug, we have to start re(de)fining tumor-targeted drug delivery alongside advances in immuno-oncology. Given that cancer is characterized by an immunological imbalance that goes beyond the primary tumor, we should focus on targeting, engaging, and modulating cancer-associated immune cells in the tumor microenvironment (TME), circulation, and immune cell-enriched tissues. When designed and applied rationally, nanomedicines will assist in restoring the immunological equilibrium at the whole-body level, which holds potential not only for cancer therapy, but also for the treatment of a range of other disorders.

KW - Animals

KW - Antineoplastic Agents/administration & dosage

KW - Drug Delivery Systems

KW - Drug Design

KW - Humans

KW - Immunotherapy/methods

KW - Nanomedicine

KW - Nanoparticles

KW - Neoplasms/drug therapy

KW - Tumor Microenvironment/immunology

U2 - 10.1016/j.drudis.2021.02.017

DO - 10.1016/j.drudis.2021.02.017

M3 - Review article

C2 - 33617793

SN - 1359-6446

VL - 26

SP - 1482

EP - 1489

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 6

ER -

A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this